Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

AeroVironment

In the labyrinth of economic dynamics, the United States finds itself in an era of immaculate disinflation. With inflation at a modest 3.2%, below expectations, and a resilient job market, the country navigates a delicate dance between growth and recession.

3 Robotics Stocks to Automate a Portfolio Full of Profits

iRobot

Rockwell Automation

The robotics sector is rapidly expanding, promising transformative potential across various industries. This article profiles three leading robotics stocks with strong growth prospect.

3 Robotics Stocks That Could Be Multibaggers in the Making

Johnson & Johnson

Ozempic could be reducing demand for weight-loss surgeries. It could thus become a new headwind for Johnson & Johnson and Intuitive Surgical.

Johnson & Johnson and Intuitive Surgical Might Become Ozempic's Next Victims. Are They Still Worth Buying?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think Intuitive Surgical, Inc. (ISRG) Is a Good Investment: Is It?

Johnson & Johnson's new surgical robot could enter clinical testing soon. In theory, it could be used for the same types of surgery as Intuitive's robot.

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?

UiPath

In the dynamic landscape of technological investments, focusing on robotics stocks to buy soon presents a captivating opportunity. As we delve into this arena, the potential for growth in companies specializing in automation and robotics is not just a trend, but a transformative shift in the global economy.

3 Robotics Stocks You'll Regret Not Buying Soon: November 2023

Merck

Merck has the tools to manage a major patent cliff that is coming in the next few years. Intuitive Surgical's leadership in its field and growth avenues make it a strong buy.

2 Healthcare Stocks That Could Make You Richer

Zacks.com users have recently been watching Intuitive Surgical, Inc. (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Most-Watched Stock Intuitive Surgical, Inc. (ISRG) Worth Betting on Now?

Ginkgo Bioworks Holdings

Moderna

Cathie Wood loves to pick up shares of innovators while they're down -- because she counts on gains over time. Wood's flagship exchange-traded fund is outperforming the S&P 500 so far this year.

3 Cathie Wood Bargain Buys That Should Be on Your List Too

Robotics and automation are a necessity for the future. Be it for operational efficiency or cost controls, companies are going to adopt automation.

3 Millionaire-Maker Robotics Stocks to Buy in November 2023

Amazon

NVIDIA

Align Technology

Advanced Micro Devices

Microsoft

NIKE

ServiceNow

When the 10-year sinks that's wehen growth names flourish. And it books like yields will keep falling.

Amazon, Nvidia, and 7 Other Stocks for Falling Bond Yields

Airbnb

Costco

Intuitive Surgical is a mature business, but its industry is still in the early stages of growth. Costco has a proven model, and current economic woes haven't detracted from its growth story.

The Best Stocks to Invest $20,000 in Right Now

Beam Therapeutics

Verve Therapeutics

Cathie Wood, the brilliant mind behind ARK Invest, is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made waves in the financial world, and millions of investors eagerly follow her every move.

Inside Cathie Wood's Portfolio: 3 Stocks She Is Betting Millions On

SUNNYVALE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Sreelakshmi Kolli, executive vice president and chief digital officer at Align Technology, to its board of directors, effective Oct. 27, 2023.

Intuitive Appoints Sreelakshmi Kolli to its Board of Directors

Brookfield Renewable Partners

MercadoLibre

The hype around artificial intelligence has slowly been fading, as investors become more familiar with the technology and the tech itself loses some of its initial awe. However, AI remains a valuable tool for uncovering new stock ideas that investors can research further, using their own analysis and intuition.

3 Stocks That AI Predicts Will Make You Very Rich

Vertex Pharmaceuticals

Healthcare businesses with wide moats and competitive advantages are compelling in any market. Vertex has several promising irons in the fire -- on top of an already profitable business.

2 Top Healthcare Stocks Defying the Bear Market

Teladoc

Vertex Pharmaceuticals is preparing for multiple blockbuster product launches in the next few years. Intuitive Surgical is gradually compounding its profits and remains the singular leader in the surgical robotics industry.

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

Intuitive Surgical (NASDAQ: ISRG) recently reported its Q3 results, with revenues lower but earnings beating our estimates.

Is Intuitive Surgical Stock A Pick After A 9% Fall In A Month Amid Mixed Q3?

Abbott Labs

Baxter

Medtronic

Stryker

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.

The Value Deepens for Medtech Stocks: Reversal Imminent

Intuitive Surgical reported third-quarter results on Thursday after U.S. markets closed. Sales rose year over year, but contracted slightly compared to the second quarter.

Intuitive Surgical's Revenue Dipped: Is It Time to Sell?

The AI boom, exemplified by companies like OpenAI and the success of generative text models like ChatGPT, was rapid, but I see challenges ahead. The AI field is now highly competitive, and these text-based AI companies might find it hard to maintain their dazzling growth.

Invest in the Robot Takeover: 3 Stocks to Buy Before They Skyrocket

Intuitive's bariatric surgeries have slowed due to weight-loss drugs, but the company doesn't see a lasting effect.

Intuitive Surgical Sees Robot Procedures Slow. Blame Wegovy and Ozempic for Now.

Analysts at the Bank of America (BoA) remain bullish on Intuitive Surgical (NASDAQ:ISRG) on its solid procedure growth and stabilization in its bariatrics segment, reiterating their ‘Buy' rating on the stock following its third quarter financial results. Investors were not impressed by maker of robotic surgical tools' 3Q financial performance, sending the stock tumbling on Thursday.

Intuitive Surgical bariatric surgeries slowdown bottoming out amid solid procedure growth

U.S. medical device makers do not see a big impact of new weight-loss treatments on the sales of equipment used in procedures such as bariatric surgery due to the prohibitive costs of the drugs as well as reimbursement hurdles.

Medical device makers see limited hit from weight-loss drugs

Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.

News for Intuitive Surgical Stock (ISRG)